Compass Pathways (NASDAQ:CMPS) Price Target Raised to $22.00

Compass Pathways (NASDAQ:CMPS) had its target price boosted by analysts at Royal Bank Of Canada from $21.00 to $22.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 100.13% from the stock’s current price.

Several other brokerages have also recently issued reports on CMPS. Canaccord Genuity Group lowered their price objective on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, March 26th. Jefferies Financial Group raised Compass Pathways to a “strong-buy” rating in a research note on Tuesday, May 5th. BTIG Research reissued a “buy” rating and set a $14.00 price objective on shares of Compass Pathways in a research note on Wednesday. Morgan Stanley reissued an “overweight” rating and set a $17.00 price objective (up from $16.00) on shares of Compass Pathways in a research note on Thursday. Finally, Compass Point set a $15.00 price objective on shares of Compass Pathways in a research note on Thursday, February 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.64.

Compass Pathways Stock Performance

CMPS stock traded up $0.03 during midday trading on Thursday, reaching $10.99. The company had a trading volume of 2,189,170 shares, compared to its average volume of 3,533,756. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. The stock has a 50 day moving average price of $7.09 and a 200 day moving average price of $6.69. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $11.28. The firm has a market capitalization of $1.42 billion, a PE ratio of -3.56 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Analysts anticipate that Compass Pathways will post -1.83 earnings per share for the current year.

Institutional Trading of Compass Pathways

Several large investors have recently added to or reduced their stakes in CMPS. Persistent Asset Partners Ltd purchased a new position in Compass Pathways during the 4th quarter valued at about $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Compass Pathways during the 4th quarter valued at $47,000. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways during the 3rd quarter valued at $41,000. Parallel Advisors LLC boosted its stake in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares during the period. Finally, North Star Investment Management Corp. boosted its stake in shares of Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after buying an additional 7,000 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

Key Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Compass Pathways reported first-quarter EPS of -$0.30, beating Wall Street estimates and suggesting better-than-expected operating performance. Earnings report and conference call
• Positive Sentiment: Management said regulatory progress continued for COMP360 in treatment-resistant depression, including an accelerated FDA review path, which is a key catalyst for the stock. Compass Pathways shares rise on Q1 results, accelerated FDA review
• Positive Sentiment: BTIG reaffirmed its Buy rating and raised its price target to $14, signaling continued analyst confidence in upside from current levels. BTIG rating update
• Neutral Sentiment: Multiple transcript and earnings-call recaps circulated after the release, reinforcing investor attention but not adding materially new information beyond the earnings update. Q1 2026 earnings call transcript

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.